You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 6,756,480


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,756,480
Title: Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
Abstract:The present invention concerns therapeutic agents that modulate the activity of PTH and PTHrP. In accordance with the present invention, modulators of PTH and PTHrP comprise: (a) a PTH/PTHrP modulating domain; and (b) a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle is covalently attached to the C-terminus of the PTH/PTHrP modulating domain. The vehicle and the PTH/PTHrP modulating domain may be linked through the N- or C-terminus of the PTH/PTHrP modulating domain, as described further below. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain. Preferred PTH/PTHrP modulating domains comprise the PTH and PTHrP-derived amino acid sequences described hereinafter. Other PTH/PTHrP modulating domains can be generated by phage display, RNA-peptide screening and the other techniques mentioned herein. Such peptides typically will be modulators of both PTH activity and PTHrP activity, although such techniques can be used to generate peptide sequences that serve as selective modulators (e.g., agonists of PTH activity but not PTHrP activity).
Inventor(s): Kostenuik; Paul (Newbury Park, CA), Liu; Chuan-Fa (Longmont, CO), Lacey; David Lee (Newbury Park, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Application Number:09/843,221
Patent Claims:1. A polypeptide comprising a parathyroid hormone (PTH) peptide and a Fc domain, wherein said Fc domain is covalently attached to the C-terminus of said PTH peptide.

2. The polypeptide of claim 1 further comprising a linker attaching said Fc domain to said PTH peptide.

3. The polypeptide of claim 1, wherein said Fc domain is an IgG Fc domain.

4. The polypeptide of claim 1, wherein said Fc domain is an IgG1 Fc domain.

5. The polypeptide of claim 1, wherein said Fc domain comprises the sequence of SEQ ID NO: 2.

6. The polypeptide of claim 1, wherein said PTH peptide is PTH-(1-84) or a fragment thereof having PTH activity.

7. The polypeptide of claim 1, wherein said PTH peptide is modified with one or more conservative amino acid substitutions.

8. The polypeptide of claim 6, wherein said PTH peptide is selected from the group consisting of PTH-(7-84), PTH-(1-44), PTH-(1-38), PTH-(2-38), PTH-(1-34), PTH-(7-34), PTH-(1-31), PTH-(1-30), PTH-(7-30), PTH-(1-29), and PTH-(1-28).

9. The polypeptide of claim 1, wherein said PTH peptide is selected from the group consisting of SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, and SEQ ID NO: 168.

10. A polypeptide comprising a parathyroid hormone-related protein (PTHrP) peptide and a Fc domain, wherein said Fc domain is covalently attached to the C-terminus of PTHrP.

11. The polypeptide of claim 10 further comprising a linker attaching said Fc domain to said PTHrP peptide.

12. The polypeptide of claim 10, wherein said Fc domain is an IgG Fc domain.

13. The polypeptide of claim 10, wherein said Fc domain is an IgG1 Fc domain.

14. The polypeptide of claim 10, wherein said Fc domain comprises the sequence of SEQ ID NO: 2.

15. The polypeptide of claim 10, wherein said PTHrP peptide is PTHrP-(1-86) or a fragment thereof having PTHrP activity.

16. The polypeptide of claim 10, wherein said PTHrP peptide is modified with one or more conservative amino acid substitutions.

17. The polypeptide of claim 10, wherein said PTHrP peptide is selected from the group consisting of PTHrP-(1-36), PTHrP-(1-34), PTHrP-(7-34), [Asn10, Leu11] PTHrP-(7-34), PTHrP-(8-34), PTHrP-(1-30), PTHrP-(7-30), and PTHrP-(8-30).

18. The polypeptide of claim 7, wherein said PTHrP peptide is SEQ ID NO: 169.

19. A polypeptide comprising a tuberoinfundibular peptide of 39 residues (TIP39 peptide) and a Fc domain, wherein said Fc domain is covalently attached to the C-terminus of said TIP39 peptide.

20. The polypeptide of claim 19, further comprising a linker attaching said Fc domain to said TIP39 peptide.

21. The polypeptide of claim 20, wherein said Fc domain is an IgG Fc domain.

22. The polypeptide of claim 20, wherein said Fc domain is an IgG1 Fc domain.

23. The polypeptide of claim 20, wherein said Fc domain comprises the sequence of SEQ ID NO: 2.

24. The polypeptide of claim 16, wherein said TIP39 peptide is SEQ ID NO: 170.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.